Publications 1999 - Earlier

These pages contain a list of publications (peer-reviewed publications and books/book chapters) generated by the faculty members during and prior to their tenure at Qatar University College of Pharmacy. A link to the abstract or open access article is typically provided at the end of the citation.

1999

Aziz AMA, Ibrahim MIM. Medication noncompliance – a thriving problem. Med J. Malaysia 1999;54:192-99.

Bayomi S M, Abdelal A M, El-Ashry S M, Ghoneim O M. Synthesis of certain new 2,4,5[6]trisubstituted 1,2,4 triazolo[1,5-a]pyrimidines as potential antihypertensive agent. Boll  Chem Farmaceutico 1999;138:227-232.

Lambert N, MacDougall C, Frighetto L, Jewesson P. Experience with ceftazidime IV-IV stepdown in the empiric treatment of febrile neutropenia: a first report. Pharmacotherapy 1999;19:641-647. (abstract)

Marra F, Frighetto L, Marra C, Sleigh K, Stiver G, Bryce G, Reynolds R, Jewesson P.  A cost-minimisation analysis of piperacillin/tazobactam vs imipemen/cilastatin for the treatment of serious infections: a Canadian hospital perspective.  Annals of Pharmacotherapy 1999;33:156-162. (abstract)

Ramesh M, Matowe WC, Wolowyk MW, Knaus EE.  Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-[4-(1- methoxycarbonyl-1,4-dihydropyridyl)]-3,5-pyridinedicarboxylates. Arch Pharm (Weinheim). 1999 Nov;332(11):385-8.

Ho AK, Hashimoto K, Matowe W, Chik CL. Adrenergic regulation of translocation of protein kinase C isozymes in rat pinealocytes Mol Cell Endocrinol. 1999 Apr 25;150(1-2):169-78.

Orabi KY, Galal A, Ibrahim AS, El-Feraly FS, Khalifa SI, ElSohly H. Microbial metabolism of artemisitene. Phytochemistry. 1999;51:257-61.

1998

Ibrahim MIM, Albert IW. Management leadership styles and effectiveness of community pharmacists: a descriptive analysis. Journal of Social and Administrative Pharmacy 1998;15:57-61.

Ibrahim MIM, Awang R, Abdul Razak D. Introducing social pharmacy courses to pharmacy students in Malaysia. Medical Teacher 1998;20:122-26.

Pillai G, Younes HM, Sallam E, Najib N. Design of oral sustained-release nifedipine using semisolid matrix systems . Int J Pharm Med 1998;155-15.

Frighetto L, Marra C, Dolman J, Jewesson P.  Addition of sevoflurane to the formulary: impact on a surgical daycare unit. Canadian Journal of Hospital Pharmacy 1998;51:160-175.

Jewesson P.  Book review of: 1996 Pocket Book of Infectious Disease Therapy (7th edition), Bartlett, JG. Williams & Wilkins, Baltimore, Maryland, U.S.A., 1996. Softcover, 343 pages. Price Unknown. Canadian Journal of Hospital Pharmacy 1998;51:123.

Marra F, Reynolds R, Stiver G, Bryce E, Sleigh K, Frighetto L, MacDougall C, Jewesson P.  Piperacillin/tazobactam vs imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital. Diagnostic Microbiology and Infectious Diseases 1998;30:355-368. (abstract)

Jewesson PJ. Overcoming antibiotic resistance: a physician's guide. Canadian Journal of CME 1998;10:137-150.

Elbe D, Frighetto L, Nickoloff D, Jewesson P. Use of cefixime in an IV to oral stepdown program to reduce antimicrobial costs. Formulary 1998;33:54-63.

Elbe D, Frighetto L,, Nickoloff D, Jewesson P. Cefixime use under the influence of an IV-PO stepdown program at a major teaching hospital. Hospital Formulary 1998;33:54-63.

Iqbal N, Akula MR, Vo D, Matowe WC, McEwen CA, Wolowyk MW, Knaus EE. Synthesis, rotamer orientation, and calcium channel modulation activities of alkyl and 2-phenethyl1,4-dihydro-2,6-dimethyl-3-nitro-4-(3- or 6-substituted-2-pyridyl)- 5-pyridinecarboxylates. J Med Chem. 1998 May 21;41(11):1827-37.

Ramesh M, Matowe WC, Akula MR, Vo D, Dagnino L, Li-Kwong-Ken MC, Wolowyk MW, Knaus EE.  Synthesis and calcium channel-modulating effects of alkyl (or cycloalkyl) 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridyl-5-pyridinecarboxylate racemates and enantiomers. J Med Chem. 1998;12;41(4):509-14.

1997

Ibrahim MIM, Wertheimer AI, Myers MJ, McGhan WF, Knowlton CH. Leadership styles and effectiveness: pharmacists in associations vs pharmacists in community settings. Journal of Pharmaceutical Marketing & Management 1997;12:23-32.

Ibrahim MIM. Primary professional care: a new approach for Malaysian pharmacists. Journal of Social & Administrative Pharmacy 1997;14:66-8.

Zjawiony JK , Khalil AA , Hufford CD , Clark AM, Buolamwini JK. Studies on methoxylation in the 7H-Naphtho[1,2,3-i,j][2,7] naphthyridin-7-one system. J. of Heterocyclic Chem. 1997; 34: 1233-1237.

Sallam E, Younes HM, Najib N, Pillai G. Design of oral sustained release nifedipine using semisolid matrix systems I .  J Control Rel 1997;48:351-352.

Jewesson P, Chow A, Wai A, Frighetto L, Nickoloff D, Smith J, Schwartz L, Sleigh K, Danforth D, Pezim M, Stoller J, Stiver G.  A Double-blind, randomized study of three antimicrobial regimens in the prevention of infections after elective colorectal surgery.  Diagnostic Microbiology and Infectious Diseases 1997;29:155-165. (abstract)

Sunstrum C, Carruthers-Czyzweski P, Members of the Human Drug AdvisoryPanel of the PMPRB - Carruthers S, Larochelle P, McLean W, Pollak T, Jewesson P, Michalko K, Thompson R. The difficulty in assessing the relative therapeutic merit of new antineoplastic drugs. Can J. Clin Pharmacol 1997; 4:118-125.

Frighetto L, Marra C, Jewesson P. Tracking and reporting drug expenditures: the messenger is as important as the message. The American Journal of Health-System Pharmacy 1997;54:2302-2306.

Marra F, Partovi N, Jewesson PJ. Aminoglycoside administration as a single daily dose (truncated rendition of Drugs 1996 publication). Medical Progress 1997;24:43-48.

Marra F, Jewesson PJ.  Piperacillin/tazobactam: can it replace imipenem on formulary? J Infect Dis Pharmacother 1997;2:55-80.

Ginsberg J, Gupta S, Matowe WC, Kline L, Brindley DN. Activation of phospholipase D in FRTL-5 thyroid cells by forskolin and dibutyryl-cyclic adenosine monophosphate. Endocrinology. 1997 138(9):3645-51.

1996

Ibrahim MIM. Pharmacists’ leadership styles and effectiveness. Journal of Social and Administrative Pharmacy 1996;13:228.

Ibrahim MIM. Treating one’s own ailments. World Health Forum 1996;17:409-10.

Committee on Antimicrobial Agents (member), Fong IW. Management of diabetic foot infection: a position paper. Canadian Journal of Infectious Diseases 1996; 7:361-365.

Committee on Antimicrobial Agents (member), Laverdiere M.Itraconazole: an oral systemic antifungal triazole: a position paper. Canadian Journal of Infectious Diseases 1996; 7:366-369.

Elbe D, Frighetto L, Nickoloff D, Jewesson P. A survey of prescriber perceptions and practice of IV-PO stepdown anti-infective therapy. Canadian Journal of Hospital Pharmacy 1996; 49:244-251.

Herar S, Jewesson P.  Pharmaceutical Industry Representative Activities at a Major Teaching Hospital.  Canadian Journal of Hospital Pharmacy 1996; 49:256-260.

Marra F, Jewesson PJ.  Vancomycin serum concentration monitoring: the middle ground is best. Clinical Drug Investigations 1996; 12:105-118.

Marra F, Partovi N, Jewesson P.  Aminoglycoside dosing as single dose: an improvement to current practice or a repeat of previous errors.  Drugs 1996; 52:344-370.

Lun E. Frighetto L, MacDougal C, Jewesson PJ. Computer-assisted retrospective clinical activities statistics (CARCAS): three years of experience. Canadian Journal of Hospital Pharmacy 1996; 49:146-150.

Malfair S, Frighetto L, Nickoloff D, Martinusen S, Jewesson P.  An Evaluation of the Use of Cefuroxime and Cefuroxime Axetil under an Intravenous-Oral Stepdown Program.  Annals of Pharmacotherapy 1996; 30:337-342.

Jewesson PJ.  Economic consequences of IV-PO stepdown therapy: focus on pefloxacin. Clin Drug Invest 1996;11(Suppl 2):1-9.

Jewesson P, Stiver G, Wai A, Frighetto L, Nickoloff D, Smith J, Schwartz L, Sleigh K, Danforth D, Scudamore C, Chow A.  Double-blind comparison of cefazolin (CFZ) and ceftizoxime (CTZ) for prophylaxis against infections following elective biliary tract surgery.  Antimicrobial Agents and Chemotherapy 1996;40:70-74.

Kheir N, Temple W, Smith N. International Programme on Chemical Safety: Poisons Information Monograph 377 Pharmaceutical (Nitrofurantoin) 1997. (link)

Kheir N. Dispensing practices in pharmacies/dispensaries in hospitals/clinics in Muscat. Oman Medical Journal 1996; 12(3): 30-32.

Matowe WC, Gupta S, Ginsberg J. Regulation of protein kinase C isoforms in FRTL-5 thyroid cells by TSH and phorbol ester. Thyroid. 1996  6(1):53-8.

1995

Marra CA, Nimmo CR, Jewesson PJ. A prospective survey of knowledge and perceptions of ondansetron:  what do healthcare workers know about this drug?  Canadian Journal of Hospital Pharmacy 1995;48:336-343.

Hufford CD, Khalifa SI, Orabi KY, Wiggers FT, Kumar R, Rogers RD, Campana CF. 1α –hydroxyarteether, a new microbial transformation product. J Nat Prod. 1995;58:751- 5.

Mandell LA, Bergeron MG, Gribble MJ, Jewesson PJ, Low DE, Marrie TJ, Nicolle LE.  Sequential antibiotic therapy:  Effective cost management and patient care.  Canadian Journal of Infectious Disease 1995;6:306-315.

Nicholl T, Reesor Nimmo C, Shepherd J, Phillips P, Jewesson P.  Influence of Infusion time on infusion-related toxicity of amphotericin B in hematology patients:  A comparison of 2 hour Vs. 4 hour Infusions.  Annals of Pharmacotherapy 1995;29:1081-1087.

Scudamore CH, Randall, T, Jewesson P, Shackleton CR, Salvian AJ, Gagan M, Frighetto L, Growe G, Scarth I, Erb SR.  Aprotinin reduces the need for blood products during liver transplantation.  American Journal of Surgery 1995;169:546-549.

Khalifa SI, Baker JK, Jung M, McChesney JD, Hufford CD. Microbial and mammalian metabolism studies of the semisynthetic antimalarial, deoxoartemisinin. J. Pharm. Res. 1995;12:1493-8.

Frighetto L, Nickoloff D, Jewesson P.  Antibiotic Therapeutic Interchange Program (TIP):  Six Years of Experience.  Hospital Formulary 1995;30:92-105.

Jewesson PJ.  Pharmaceutical, pharmacokinetic and other considerations for intravenous to oral stepdown therapy.  Canadian Infectious Diseases Journal 1995;6(Suppl A):11A-16A.

Frighetto L, Martinusen S, Mamdani F, Jewesson P.  Ciprofloxacin use under a reserved drug and stepdown promotion program.  The Canadian Journal of Hospital Pharmacy 1995;48:35-42.

Masri BA, Duncan CP, Jewesson PJ, Ngui-Yen J, Smith J. Streptomycin-loaded bone cement in the treatment of tuberculous osteomyelitis: a new method of delivery. Canadian Journal of Surgery 1995;38:64-68.

Gupta S, Gomez-Munoz A, Matowe WC, Brindley DN, Ginsberg J. Thyroid-stimulating hormone activates phospholipase D in FRTL-5 thyroid cells via stimulation of protein kinase C. Endocrinology. 1995 Sep;136(9):3794-9.

Vo D, Matowe WC, Ramesh M, Iqbal N, Wolowyk MW, Howlett SE, Knaus EE. Syntheses, calcium channel agonist-antagonist modulation activities, and voltage-clamp studies of isopropyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridinylpyridine-5-carboxylate racemates and enantiomers. J Med Chem. 1995 21;38(15):2851-9.

Matowe WC, Ginsberg J, Increased membrane-bound protein kinase C in porcine thyroid cells following TSH exposure. Clin Invest Med. 1995 18(3):186-92.

1994 

Al-Rashood KA , Abdel-Moety EM , Al-deeb OA , Khalil AA, Khattab NA. Derivative spectrophotometry for stability-indicating determination of norfloxacin in bulk form and tablets. Scientia Pharmaceutica (Sci. Pharm.)1994; 62: 225-235.

Leong W, Jewesson P.  A Retrospective Evaluation of Imipenem Use in Bone Marrow Transplant Patients.  Clinical Therapeutics:  The International Journal of Drug Therapy 1994;16:752-766.

Khalifa SI, Baker JK, Rogers RD, El-Feraly FS, Hufford CD. Microbial and mammalian metabolism studies of semisynthetic antimalarial, anhydrodihydroartemisinin. J Pharm Res. 1994;11:990-4.

Jewesson P.  Cost-Effectiveness and Value of an IV Switch.  PharmacoEconomics 1994;5(Suppl.2):20-26.

Rayani S, Reesor Nimmo C, Frighetto L, Martinusen S, Nickoloff D, Reece D, Jewesson P.  Implementation and evaluation of a standardized HSV prophylaxis protocol on a leukemia/bone marrow transplant unit.  Annals of Pharmacotherapy 1994;28:852-6.

Nicholl T, Phillips P, Jewesson P.  Amphotericin B use in a major acute care hospital. Clinical Therapeutics: The International Journal of Drug Therapy 1994;16:28-40.

Kheir N. Patient Compliance: definition, reasons, and suggested solutions. Oman Medical Journal 1994; 11(1): 48-50

1993

Al-Deeb OA , Al-Rashood KA, Khalil AA. Synthesis of new (1-phenylcyclohexyl) piperazine as potential analgesics. Bull. of Fac. Pharm., Cairo Univ.1993; 31: (3) 475-479.

Chow AW, Jewesson P, Kureishi A, Phillips GL.  Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients.  Eur J Haematol 1993;51:18-24.

Reesor Nimmo C, Jewesson P.  Documenting pharmacists' activities in the health record:  a mechanism to provide ongoing quality assurance.  The Annals of Pharmacotherapy 1993;27:1405-1406.

Reesor C, Mamdani F, Baker A, Jewesson P. Development and implementation of empiric aminoglycoside dosing guidelines. Pharmacotherapy 1993;13:408-414.

Donaldson M, Hope J, Jewesson P. Computer-assisted retrospective clinical activities statistics (CARCAS) program. Canadian Journal of Hospital Pharmacy 1993;46:17-22.

Hufford CD, Khalifa SI, McPhail AT, El-Feraly FS, Ahmed MS. Preparation and characterization of new C11-oxygenated artemisinin derivatives. J Nat Prod. 1993;56:62- 6.

Martinusen S, Chen D, Frighetto L, Bunz D, Stiver G, Jewesson P. A comparison of cefoxitin and ceftizoxime in a hospital therapeutic interchange program. Canadian Medical Association Journal 1993;148:1161-1169. (Recipient of 1990 B.C. Residency Project Award/Upjohn and C.S.H.P. National Residency Project Award 1990)/Organon.

Jobin RM, Ginsberg J, Matowe WC, Chang JP. Downregulation of protein kinase C levels leads to inhibition of GnRH-stimulated gonadotropin secretion from dispersed pituitary cells of goldfish. Neuroendocrinology 1993 Jul;58(1):2-10.

Ginsberg J, Matowe W, Murray PG. Enhancement of thyrotropin-stimulated iodide organification in porcine thyroid cells after protein kinase-C inhibition. Endocrinology 1993 132(4):1815-9.

1992

Al-deeb OA , Abdel-Moety EM , Khattab NA, Khalil AA. Potentiometric titrimetry for simultaneous determination of ampicillin and dicloxacillin in bulk and in capsules. Acta Pharmaceutica Fennica. 1992; 101: 215-219.

Frighetto L, Bunz D, Martinusen S, Mamdani F, Jewesson P. IV-PO stepdown program: results of four years of experience.  The Annals of Pharmacotherapy 1992;26:1447-51.

McCormack J, Jewesson P. A critical reevaluation of the "therapeutic range" of aminoglycosides. Reviews of Infectious Diseases 1992;14:320-339.

Ramesh M, Matowe WC, Knaus EE, Wolowyk MW. Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-[3-(1-methoxy- carbonyl-4-substituted-1,4-dihydro-pyridyl)]-3,5-pyridinedicarboxylates. Drug Des Discov 1992 8(4):313-23.

1991

Kureishi A, Jewesson P, Cole C, Reece D, Phillips G, Smith J, Chow A. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity. Antimicrobial Agents and Chemotherapy 1991;35:2246-2252. (R).

Gutensohn A, Bunz D, Frighetto L, Jewesson P. Outcome of a ceftriaxone/cefotaxime interchange programme in a major teaching hospital. Chemotherapy 1991;37(Suppl 3):15-21. (Recipient of 1991 B.C. Branch, Canadian Society of Hospital Pharmacists Publication Award).

1990

Frighetto L, Bunz D, Jewesson P. Prescriber identification program. Canadian Journal of Hospital Pharmacy 1990;44:35-36.

Kureishi A, Jewesson P, Bartlett K, Cole C, Chow A. Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients. Antimicrobial Agents and Chemotherapy 1990;34:1642-1647.

Phillips P, Dowd A, Jewesson P, Radigan G, Tweeddale M, Clarke A, Geere I, Kelly M. Nonvalue of antigen detection immunoassays for diagnosis of candidemia. Journal of Clinical Microbiology 1990;28:2320-2326.

Vandevelde C, Chang A, Andrews D, Riggs W, Jewesson P. Rifampin and ansamycin interactions with cyclosporine in a renal transplant patient. Pharmacotherapy. The Journal of Human Pharmacology and Drug Therapy 1990;11:88-89.

Bunz D, Gupta S, Jewesson P. Metronidazole cost containment: a two-stage intervention. Hospital Formulary 1990;25:1167-77.

Member, Working Committee. Guidelines for antimicrobial utilization in health care facilities. Canadian Journal of Infectious Diseases 1990;1:64-70.

Member, Working Committee. Infection control guidelines. Antimicrobial utilization in health care facilities. Health and Welfare Canada 1990:1-22.

Bunz D, Frighetto L, Gupta S, Jewesson P. Simple ways to promote cost containment. Drug Intelligence and Clinical Pharmacy, The Annals of Pharmacotherapy 1990;24:546.

Akula MR, Matowe WC, Wolowyk MW, Knaus EE. Synthesis and calcium channel antagonist activity of nifedipine analogues containing 4-pyridyl and 3- arylethyloxycarbonyl substituents.  Drug Des Deliv. 1990 Dec;7(1):11-7.

Akula MR, Matowe WC, Wolowyk MW, Knaus EE. Synthesis and calcium channel antagonist activity of 3-arylmethyl 5-isopropyl 1,4-dihydro-2,6-dimethyl-4- (pyridyl)-3,5-pyridinedicarboxylates. Pharm Res. 1990 7(9):919-22.

1989

Bowie W, Willetts V, Jewesson P. Adverse reactions in a dose-ranging study with a new long acting fluoroquinolone, fleroxacin. Antimicro Agents Chemother 1989;33:1778-1782.

Jewesson PJ. Facilitating drug-use evaluation with database and other software (brief correspondence). Am J Hosp Pharm 1989; 46:1549.

Bunz D, Gupta S, Jewesson PJ. Physician and nurse awareness of drug-use-review activities (brief correspondence). Am J Hosp Pharm 1989;46:1125-1126.

Shalansky S, Gupta S, Jewesson P. Impact of a practical two-stage therapeutic interchange program on aminoglycoside usage. Hosp Form 1989;24:332-341.

Gupta S, Bachand R, Jewesson P. Impact of a two?stage intervention on cefazolin usage at a major teaching hospital. Hosp Form 1989;24:41-46.

Akula MR, Matowe WC, Wolowyk MW, Knaus EE. Synthesis and calcium channel antagonist activity of alkyl cycloalkyl esters of nifedipine containing pyridinyl substituents. Drug Des Deliv. 1989 5(2):117-23.

Matowe WC, Akula M, Knaus EE, Wolowyk MW. AK-2-38, a nifedipine analogue with potent smooth muscle calcium antagonist action and partial agonist effects on isolated guinea pig left atrium. Proc West Pharmacol Soc. 1989;32:305-7.

Al-Said M, Khalifa SI, El-Feraly FS, Hufford CD. Biogenetic-type synthesis of vulgarin and peroxyvulgarin. Phytochemistry. 1989;28:107-8.
 

Al-Said M, Khalifa SI, El-Feraly FS. 4,13-α –epoxymuzigadial, a sesquiterpene from Canella winterana. Pytochemistry. 1989;28:297-8.

El-Feraly FS, Al-Meshal IA, Khalifa SI. Epi-deaoxoarteannuin B and 6,7- dehydroartemisinic acid from Artemisia annua. J Nat Prod. 1989;52:196-8.

1988

Reesor C, Chow A, Jewesson P.  Intraventricular vancomycin kinetics in CSF shunt infections.  J Infect Dis 1988; 158:1142?1143.

Zaremba C, Bachand R, Chow A, Jewesson P.  Drug usage review of cefamandole at a major teaching hospital. Can J Hosp Pharm 1988;41:195?199,214.

Gupta S, Bachand R, Jewesson P. Unique two?stage intervention to modify prescribing trends (brief correspondence). Drug Intel Clin Pharm 1988;22:726?727.

Ramesh M, Matowe WC, Wolowyk MW, Knaus EE. Synthesis and calcium channel antagonist activity of nifedipine analogues containing 1-oxido-2-pyridyl in place of the 2-nitrophenyl moiety. Drug Des Deliv. 1988 3(4):337-41.

Wynn H, Ramesh M, Matowe WC, Wolowyk MW, Knaus EE. Synthesis and calcium channel antagonist activity of 1,2-dihydropyridyl analogues of nifedipine. Drug Des Deliv. 1988 3(3):245-56.

Al-Said MS, Abdelsattar, EA, Khalifa SI, El-Feraly FS. Isolation and identification of an anti-inflammatory principle from Capparis spinosa. Pharmazie. 1988;43:640-1.

1987

Jewesson PJ, Chow AWC.  Use and safety of metronidazole during pregnancy (brief correspondence). West J Med 1987;147;599?600.

Bachand RL, Jewesson PJ, Chow AW.  Implementation of a reserved antimicrobial drug program.  Can J Hosp Pharm 1987;40:167?170.

Ensom RJ, Jewesson PJ, Miyata M, Hlynka JN, Ruedy J, Kennedy J. Theophylline dosing:  Efforts to improve prescribing practices.  Can J Hosp Pharm 1987; 40:47?50.

Remick R, Jewesson P, Ford R. Re-evaluation of the concomitant use of MAO inhibitors in general anesthesia Convulsive Therapy 1987;3:196?203.

Chow AW, Jewesson PJ.  Use and Safety of antimicrobial agents during pregnancy. West J Med 1987; 146: 761-4.

Ramesh M, Matowe WC, Wolowyk MW, Knaus EE. Synthesis and calcium channel antagonist activity of alkyl t-butyl esters of nifedipine analogues containing pyridinyl substituents. Drug Des Deliv. 1987 2(2):79-89.

1986

Jewesson PJ.  Prescribing in the community hospital:  Evaluation of the impact of modification strategies on prescribing patterns.  University of British Columbia:  Vancouver, Canada. Ph.D. Thesis, 1986.

Ensom RJ, Jewesson PJ, Hlynka JN, Ruedy J, Kennedy J.  Effect of pharmacist intervention on appropriateness of parenteral cimetidine use.  Can J Hosp Pharm 1986;39:6?8.

1985

Jewesson PJ, Ensom RJ.  Influence of bodyfat on the volume of distribution of theophylline.  Ther Drug Monit 1985;7:197?201.

Jewesson PJ, Remick RA.  Serum level monitoring of tricyclic antidepressant therapy.  B C Med J 1985;27:638?640.

Jewesson PJ, Bachand R, Chow AW.  Evaluation of parenteral metronidazole in an acute care teaching hospital.  Can Med Assoc J 1985;132:785?789.

Jewesson PJ, Remick RA, Seccombe JW, Godolphin W. Ensom RJ.  Clinical application of tricyclic antidepressant levels:  a Canadian experience.  Can J Hosp Pharm 1985;38:156?159.

Ensom RJ, Jewesson PJ.  Influence of a hospital pharmacy residency on career advancement and satisfaction.  Can J Hosp Pharm 1985;2:5?9.

Chow AW, Jewesson PJ.  Pharmacokinetics and safety of antimicrobial agents during pregnancy.  Rev Infect Dis 1985;7:287?313.

Jewesson PJ, Chow AW.  Safety of antimicrobial agents during pregnancy.  The Medical Letter 1985; 27:93?95.

1983

Jewesson PJ, Chow AW.  Dealing with the misuse of antibiotics in the hospital.  Can Med Assoc Journal 1983;128:1061?62.

Jewesson PJ, Chow AW.  Auditing antibiotic use in a teaching hospital:  focus on cefoxitin.  Can Med Assoc J 1983;128:1075?78.

1982

Bachand R, Jewesson PJ.  Handling of new antineoplastic agents:  who do we protect.  (brief correspondence) Can J Hosp Pharm 1982;35:166. 

JIP Archive